Evidence map›Paper›PMID 30108133›Full record

ArticleMolecular cancer therapeutics2018

Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog.

Mohamed Y Elsaid, Ankita Shahi, Albert R Wang, Dana C Baiu, Chunrong Li, Lauryn R Werner, Sorabh Singhal, Lance T Hall, Jamey P Weichert, Eric A Armstrong and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Mohamed Y Elsaid *Division of Hematology, Oncology & Bone Marrow Transplant, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Ankita Shahi *Division of Hematology, Oncology & Bone Marrow Transplant, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Albert R WangDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Dana C BaiuDivision of Hematology, Oncology & Bone Marrow Transplant, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Chunrong LiDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Lauryn R WernerDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Sorabh SinghalDivision of Hematology, Oncology & Bone Marrow Transplant, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Lance T HallDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Jamey P WeichertDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Eric A ArmstrongDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Bryan P BednarzDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Paul M HarariDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Gopal IyerDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Mario OttoDivision of Hematology, Oncology & Bone Marrow Transplant, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. motto@pediatrics.wisc.edu.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI YU, MENGGANG · 2016 to 2020
$10.8M
A cancer-targeted phospholipid ether analog for molecular radiotherapy of pediatric solid tumorsR21CA198392 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEDNARZ, BRYAN PATRICK, OTTO, MARIO · 2015 to 2016
$366k
NCI NIH HHS P30 CA014520NCI NIH HHS R21 CA198392NIDCR NIH HHS P50 DE026787
6 · The paper itself

Abstract

Antitumor alkyl phospholipid (APL) analogs comprise a group of structurally related molecules with remarkable tumor selectivity. Some of these compounds have shown radiosensitizing capabilities. CLR127 is a novel, clinical-grade antitumor APL ether analog, a subtype of synthetic APL broadly targeting cancer cells with limited uptake in normal tissues. The purpose of this study was to investigate the effect of CLR127 to modulate radiation response across several adult and pediatric cancer types

Indexed as

Radiation ToleranceAnimalsCell Line, TumorCell ProliferationCell SurvivalClone CellsDNA DamageHistonesHumansMice, NudeNeoplasmsPhospholipid EthersXenograft Model Antitumor AssaysX-RaysH2AX protein, humanHistonesPhospholipid Ethers

Identifiers

PMID30108133
PMCPMC6215514
OpenAlexW2898798870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.